Hyaluronidase access in 2025: When regulatory reality challenges clinical safety in esthetic medicine

Hyaluronic acid (HA) fillers are among the most widely performed aesthetic procedures globally. Their clinical safety rests on the reversibility of the product, a property that depends entirely on the availability of hyaluronidase, the sole pharmacological agent capable of dissolving HA deposits rapidly and predictably. International guidelines consistently designate immediate on-site hyaluronidase availability as an essential component of safe practice, particularly for the management of filler-induced vascular occlusion, a rare but potentially sight- and tissue-threatening complication. This narrative review examines the documented mismatch between these clinical standards and real-world access conditions in 2025, with particular focus on the German and broader European regulatory environment. A review of peer-reviewed literature, clinical guidelines, regulatory documentation, and expert consensus statements was conducted; grey-literature sources including official shortage registers and professional society notifications are incorporated where they constitute the most current available evidence. Access barriers documented across multiple institutional and regulatory sources include restrictive prescription frameworks, fragmented supply chains, and regulatory classifications that do not reflect hyaluronidase’s emergency rescue function. In Germany, the “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) i.e., Federal Institute for Drugs and Medical Devices, officially documented Hylase ® Dessau shortages during 2023; in June 2025, the Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) i.e, German Society for Haematology and Medical Oncology notified clinicians that the sole commercially available preparation had ceased production entirely. These developments indicate a structural gap between procedural risk and reversal agent availability, with direct implications for patient safety, practitioner liability, and the informed consent framework of reversible aesthetic medicine. Regulatory frameworks governing hyaluronidase access do not currently reflect its clinical function as an emergency reversal agent. Structured access pathways, supply chain measures, and integration of preparedness standards into licensing frameworks would better align regulatory structures with established standards of care.